BackgroundTreatment with anti-EGFR antibody has been shown to prolong survival in patients with RAS wild-type metastatic colorectal cancer (mCRC). However. even patients who initially respond to anti-EGFR antibody therapy. almost without exception. https://www.spidertattooz.com/Army-Patch-44th-Infantry-Brigade-Combat-Team-embroidered-on-OCP/